Frazier Financial Advisors’s Biogen BIIB Stock Holding History

Frazier Financial Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$928	–	875
2024 Q2	$928	Buy	+4	New	+$869	﹤0.01%	862

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Frazier Financial Advisors's BIIB Position: Q3 2024 in Review

Frazier Financial Advisors sold out of Biogen (BIIB) in Q3 2024, closing a stake of 4 shares — an estimated $928 sold.

Frazier Financial Advisors first reported a position in BIIB in Q2 2024 and held it in 1 quarter. The position peaked at $928 in Q2 2024. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Frazier Financial Advisors reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Frazier Financial Advisors sold 4 Biogen shares in Q3 2024, an estimated $928.
Frazier Financial Advisors first reported a position in Biogen in Q2 2024 and held it in 1 quarter.
Frazier Financial Advisors's Biogen position peaked at $928 in Q2 2024.
916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Frazier Financial Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.